Suppr超能文献

保险审批对质子束治疗的影响及其对治疗延误的影响。

Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.

机构信息

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):714-723. doi: 10.1016/j.ijrobp.2018.12.021. Epub 2018 Dec 14.

Abstract

PURPOSE

Prior authorization (PA) has been widely implemented for proton beam therapy (PBT). We sought to determine the association between PA determination and patient characteristics, practice guidelines, and potential treatment delays.

METHODS AND MATERIALS

A single-institution retrospective analysis was performed of all patients considered for PBT between 2015 and 2018 at a National Cancer Institute-designated Comprehensive Cancer Center. Differences in treatment start times and denial rates over time were compared, and multivariable logistic regression was used to identify predictors of initial denial.

RESULTS

A total of 444 patients were considered for PBT, including 396 adult and 48 pediatric patients. The American Society for Radiation Oncology model policy supported PBT coverage for 77% of the cohort. Of adult patients requiring PA, 64% were initially denied and 32% remained denied after appeal. In patients considered for reirradiation or randomized phase 3 trial enrollment, initial denial rates were 57% and 64%, respectively. Insurance coverage was not related to diagnosis, reirradiation, trial enrollment, or the American Society for Radiation Oncology model policy guidelines, but it was related to insurance category on multivariable analysis (P < .001). Over a 3-year timespan, initial denial rates increased from 55% to 74% (P = .034). PA delayed treatment start by an average of 3 weeks (and up to 4 months) for those requiring appeal (P < .001) and resulted in 19% of denied patients abandoning radiation treatment altogether. Of pediatric patients, 9% were initially denied, all of whom were approved after appeal, and PA requirement did not delay treatment start (P = .47).

CONCLUSIONS

PA requirements in adults represent a significant burden in initiating PBT and cause significant delays in patient care. Insurance approval is arbitrary and has become more restrictive over time, discordant with national clinical practice guidelines. Payors and providers should seek to streamline coverage policies in alignment with established guidelines to ensure appropriate and timely patient care.

摘要

目的

质子束治疗(PBT)已广泛实施了预先授权(PA)。我们旨在确定 PA 决策与患者特征、实践指南和潜在治疗延迟之间的关联。

方法和材料

对 2015 年至 2018 年间在一家美国国立癌症研究所指定的综合性癌症中心考虑接受 PBT 的所有患者进行了单机构回顾性分析。比较了随时间推移的治疗开始时间和拒绝率的差异,并使用多变量逻辑回归来确定初始拒绝的预测因素。

结果

共有 444 名患者被考虑接受 PBT,包括 396 名成年患者和 48 名儿科患者。美国放射肿瘤学会(ASTRO)模型政策支持该队列中 77%的患者接受 PBT 覆盖。需要 PA 的成年患者中,64%的患者最初被拒绝,32%的患者在上诉后仍被拒绝。在考虑再放疗或随机 3 期试验入组的患者中,初始拒绝率分别为 57%和 64%。保险覆盖与诊断、再放疗、试验入组或 ASTRO 模型政策指南无关,但在多变量分析中与保险类别有关(P<0.001)。在 3 年的时间跨度内,初始拒绝率从 55%增加到 74%(P=0.034)。对于需要上诉的患者,PA 平均延迟治疗开始时间 3 周(最长可达 4 个月)(P<0.001),并导致 19%的拒绝患者完全放弃放疗。在儿科患者中,9%的患者最初被拒绝,所有患者在上诉后都获得了批准,并且 PA 要求没有延迟治疗开始(P=0.47)。

结论

成人的 PA 要求代表了启动 PBT 的重大负担,并导致患者护理的重大延迟。保险批准是任意的,并且随着时间的推移变得更加严格,与国家临床实践指南不一致。支付方和提供者应寻求简化与既定指南一致的覆盖政策,以确保适当和及时的患者护理。

相似文献

1
Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):714-723. doi: 10.1016/j.ijrobp.2018.12.021. Epub 2018 Dec 14.
2
The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):724-733. doi: 10.1016/j.ijrobp.2018.12.019. Epub 2018 Dec 14.
3
Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy.
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1496-1504. doi: 10.1016/j.ijrobp.2021.02.049. Epub 2021 Mar 4.
4
Proton therapy expansion under current United States reimbursement models.
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):235-40. doi: 10.1016/j.ijrobp.2014.02.014. Epub 2014 Mar 27.
5
Insurance coverage decisions for pediatric proton therapy.
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26729. Epub 2017 Aug 7.
6
Patterns of Proton Beam Therapy Use in Clinical Practice between 2007 and 2019 in Korea.
Cancer Res Treat. 2021 Oct;53(4):935-943. doi: 10.4143/crt.2021.409. Epub 2021 May 17.
7
Doing poorly by doing good: the bottom line of proton therapy for children.
J Am Coll Radiol. 2014 Oct;11(10):995-7. doi: 10.1016/j.jacr.2014.04.004. Epub 2014 Jun 2.
9
Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies.
Pract Radiat Oncol. 2020 Sep-Oct;10(5):324-329. doi: 10.1016/j.prro.2019.08.005. Epub 2019 Aug 22.

引用本文的文献

1
Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact.
Explor Target Antitumor Ther. 2025 Aug 28;6:1002334. doi: 10.37349/etat.2025.1002334. eCollection 2025.
3
Proton Therapy Patient Selection Methods and the Impact of COVID-19: A Cross-Sectional International Survey.
J Med Radiat Sci. 2025 Sep;72(3):333-340. doi: 10.1002/jmrs.885. Epub 2025 May 11.
4
Radiotherapy Utilization in Traditional Medicare and Medicare Advantage.
JAMA Netw Open. 2025 Apr 1;8(4):e253018. doi: 10.1001/jamanetworkopen.2025.3018.
5
Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies.
Int J Part Ther. 2025 Feb 17;15:100741. doi: 10.1016/j.ijpt.2025.100741. eCollection 2025 Mar.
6
The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence From Radiation Oncology.
Adv Radiat Oncol. 2024 Oct 23;10(1):101654. doi: 10.1016/j.adro.2024.101654. eCollection 2025 Jan.
7
Novel use of adjuvant proton beam therapy in patient with pelvic renal transplant diagnosed with stage IB3 cervical adenocarcinoma.
Gynecol Oncol Rep. 2024 Sep 29;56:101520. doi: 10.1016/j.gore.2024.101520. eCollection 2024 Dec.
8
How Long Can You Delay? Curve Progression While Awaiting Vertebral Body Tethering Surgery.
J Clin Med. 2024 Apr 11;13(8):2209. doi: 10.3390/jcm13082209.
9
How proton therapy fits into the management of adult intracranial tumors.
Neuro Oncol. 2024 Mar 4;26(12 Suppl 2):S26-S45. doi: 10.1093/neuonc/noad183.
10
Prompt Pain Relief From Bone Metastases: The Virtual Simulation Program.
Adv Radiat Oncol. 2023 Aug 25;9(2):101361. doi: 10.1016/j.adro.2023.101361. eCollection 2024 Feb.

本文引用的文献

3
Three ways to make proton therapy affordable.
Nature. 2017 Sep 25;549(7673):451-453. doi: 10.1038/549451a.
4
Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation.
Radiother Oncol. 2017 Oct;125(1):21-30. doi: 10.1016/j.radonc.2017.08.005. Epub 2017 Sep 20.
5
Insurance coverage decisions for pediatric proton therapy.
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26729. Epub 2017 Aug 7.
6
Charged-particle therapy in cancer: clinical uses and future perspectives.
Nat Rev Clin Oncol. 2017 Aug;14(8):483-495. doi: 10.1038/nrclinonc.2017.30. Epub 2017 Mar 14.
7
Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials.
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):228-235. doi: 10.1016/j.ijrobp.2016.10.045. Epub 2016 Nov 8.
8
Beyond a moonshot: insurance coverage for proton therapy.
Lancet Oncol. 2016 May;17(5):559-61. doi: 10.1016/S1470-2045(16)00171-6. Epub 2016 Apr 27.
9
A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
Cancer. 2016 May 15;122(10):1483-501. doi: 10.1002/cncr.29882. Epub 2016 Feb 1.
10
Reference pricing with evidence development: a way forward for proton therapy.
J Clin Oncol. 2014 May 20;32(15):1540-2. doi: 10.1200/JCO.2014.55.6613. Epub 2014 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验